Monoclonal antibodies

A potentially powerful tool in the diagnosis and treatment of infectious diseases

G. Spira, R. R. Pollock, A. Bargellesi, Matthew D. Scharff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The hybridoma technology has made it possible to generate superior serological reagents in large amounts and to have the same reagents available indefinitely. Such monoclonal antibodies are very useful in diagnosis and epidemiology. Monoclonals have also made it possible to identify the sequences on infectious agents that are responsible for their infectivity and to generate and study both polypeptide and idiotypic vaccines. Once human monoclonals can be easily generated and produced, passive immunization may again become a major therapeutic tool.

Original languageEnglish (US)
Pages (from-to)251-256
Number of pages6
JournalEuropean Journal of Clinical Microbiology
Volume4
Issue number3
DOIs
StatePublished - Jun 1985

Fingerprint

Communicable Diseases
Monoclonal Antibodies
Passive Immunization
Hybridomas
Epidemiology
Vaccines
Technology
Peptides
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Monoclonal antibodies : A potentially powerful tool in the diagnosis and treatment of infectious diseases. / Spira, G.; Pollock, R. R.; Bargellesi, A.; Scharff, Matthew D.

In: European Journal of Clinical Microbiology, Vol. 4, No. 3, 06.1985, p. 251-256.

Research output: Contribution to journalArticle

@article{54f11717012343ed996c6afd6b29affd,
title = "Monoclonal antibodies: A potentially powerful tool in the diagnosis and treatment of infectious diseases",
abstract = "The hybridoma technology has made it possible to generate superior serological reagents in large amounts and to have the same reagents available indefinitely. Such monoclonal antibodies are very useful in diagnosis and epidemiology. Monoclonals have also made it possible to identify the sequences on infectious agents that are responsible for their infectivity and to generate and study both polypeptide and idiotypic vaccines. Once human monoclonals can be easily generated and produced, passive immunization may again become a major therapeutic tool.",
author = "G. Spira and Pollock, {R. R.} and A. Bargellesi and Scharff, {Matthew D.}",
year = "1985",
month = "6",
doi = "10.1007/BF02013647",
language = "English (US)",
volume = "4",
pages = "251--256",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "3",

}

TY - JOUR

T1 - Monoclonal antibodies

T2 - A potentially powerful tool in the diagnosis and treatment of infectious diseases

AU - Spira, G.

AU - Pollock, R. R.

AU - Bargellesi, A.

AU - Scharff, Matthew D.

PY - 1985/6

Y1 - 1985/6

N2 - The hybridoma technology has made it possible to generate superior serological reagents in large amounts and to have the same reagents available indefinitely. Such monoclonal antibodies are very useful in diagnosis and epidemiology. Monoclonals have also made it possible to identify the sequences on infectious agents that are responsible for their infectivity and to generate and study both polypeptide and idiotypic vaccines. Once human monoclonals can be easily generated and produced, passive immunization may again become a major therapeutic tool.

AB - The hybridoma technology has made it possible to generate superior serological reagents in large amounts and to have the same reagents available indefinitely. Such monoclonal antibodies are very useful in diagnosis and epidemiology. Monoclonals have also made it possible to identify the sequences on infectious agents that are responsible for their infectivity and to generate and study both polypeptide and idiotypic vaccines. Once human monoclonals can be easily generated and produced, passive immunization may again become a major therapeutic tool.

UR - http://www.scopus.com/inward/record.url?scp=0022262941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022262941&partnerID=8YFLogxK

U2 - 10.1007/BF02013647

DO - 10.1007/BF02013647

M3 - Article

VL - 4

SP - 251

EP - 256

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 3

ER -